Quick Answer
ENDRA Life Sciences Inc. reported Diluted EPS of $8.93 per share (loss) for fiscal year 2025.
ENDRA Life Sciences Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$8.93 | +84.3% |
| 2024 | -$56.94 | +97.9% |
| 2023 | -$2766.85 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$2.10 | +78.0% | +78.0% |
| September 30, 2024 | -$9.54 | — | — |
- ENDRA Life Sciences Inc. showed an increase of +84.3% in Diluted EPS compared to the prior fiscal year.
- Over the 2023–2025 period, ENDRA Life Sciences Inc.’s diluted eps has grown by 99.7% (from $2766.85 per share (loss) to $8.93 per share (loss)).
- The most recent figure is from ENDRA Life Sciences Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: